# Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

> **NCT00927901** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Indacaterol maleate 400 μg
- **DRUG:** Indacaterol acetate 400 μg
- **DRUG:** Indacaterol xinafoate 400 μg
- **DRUG:** Placebo to indacaterol

## Key facts

- **NCT ID:** NCT00927901
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927901, "Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00927901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*